U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Yea... (p For more information and FUL...)

HOME >> MEDICINE >> TECHNOLOGY

U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)

Date:2/29/2008

For more information and FULL PRESCRIBING INFORMATION,

including Boxed WARNINGS, visit: http://www.abilify.com

Visit Otsuka Pharmaceutical Co., Ltd. at: http://www.otsuka-global.com

Visit Bristol-Myers Squibb at: http://www.bms.com

February 2008 0308N-0662

* The Y-MRS is a standard measure that is an 11-item rating scale used by healthcare providers to assess the scope and severity of manic symptoms.(1) Y-MRS Total Scores range from 0 (no manic symptoms) to 60 (severe mania).(2)
(1) Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for

mania: reliability, validity, and sensitivity. Br J Psychiatry.

1978;133:429-435.

(2) Rush AJ, et al. Handbook of Psychiatric Measures. Washington, DC:

American Psychiatric Association; 2000.

References

(1) Kumra S, Oberstar JV, Sikich L, Findling RL, McClellan JM, Vinogradov

S, Schulz SC. Efficacy and Tolerability of Second-Generation

Antipsychotics in Children and Adolescents With Schizophrenia.

Schizophrenia Bulletin. Published online October 8, 2007.

(2) IMS Auditrac NGPS: ABILIFY total monthly retail prescriptions: Data

accessed December 2007.

1

GOOD

Page: 1 2 3 4 5 6 7 8 9
Related medicine technology :

1. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
2. Supplemental New Drug Application for PREZISTA(TM) Submitted to U.S. Food and Drug Administration
3. Northwestern Offers Clinical Research and Regulatory Administration Graduate Certificate Program
4. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
5. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
6. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
7. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
8. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
9. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
10. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice

Post Your Comments:

U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Yea...(p For more information and FUL...),Health